Limits...
Efficacy of add-on montelukast in nonasthmatic eosinophilic bronchitis: the additive effect on airway inflammation, cough and life quality.

Bao W, Liu P, Qiu Z, Yu L, Hang J, Gao X, Zhou X - Chin. Med. J. (2015)

Bottom Line: After 2-week treatment, add-on treatment of MONT was significantly more effective than BUD monotherapy for CVAS decrease and LCQ scores improvement (both P < 0.05).Similar results were seen at 4-week assessment (both P < 0.05). 4-week add-on therapy of MONT also resulted in a higher percentage of patients with normal sputum Eos (<2.5%) and greater decrease of ECP (both P < 0.05).MONT combined with BUD was demonstrated cooperative effects in improvement of life quality, suppression of eosinophilic inflammation, and cough remission in patients with NAEB.

View Article: PubMed Central - PubMed

Affiliation: Department of Respiratory Medicine, Shanghai First People's Hospital, Shanghai Jiao Tong University, Shanghai 200080, China.

ABSTRACT

Background: The efficacy of montelukast (MONT), a cysteinyl leukotriene receptor antagonist, in nonasthmatic eosinophilic bronchitis (NAEB), especially its influence on cough associated life quality is still indefinite. We evaluated the efficacy of MONT combined with budesonide (BUD) as compared to BUD monotherapy in improving life quality, suppressing airway eosinophilia and cough remission in NAEB.

Methods: A prospective, open-labeled, multicenter, randomized controlled trial was conducted. Patients with NAEB (aged 18-75 years) were randomized to inhaled BUD (200 μg, bid) or BUD plus oral MONT (10 μg, qn) for 4 weeks. Leicester cough questionnaire (LCQ) life quality scores, cough visual analog scale (CVAS) scores, eosinophil differential ratio (Eos), and eosinophil cationic protein (ECP) in induced sputum were monitored and compared.

Results: The control and MONT groups contained 33 and 32 patients, respectively, with similar baseline characteristics. Significant with-in group improvement in CVAS, LCQ scores, Eos, and ECP was observed in both groups during treatment. After 2-week treatment, add-on treatment of MONT was significantly more effective than BUD monotherapy for CVAS decrease and LCQ scores improvement (both P < 0.05). Similar results were seen at 4-week assessment (both P < 0.05). 4-week add-on therapy of MONT also resulted in a higher percentage of patients with normal sputum Eos (<2.5%) and greater decrease of ECP (both P < 0.05).

Conclusions: MONT combined with BUD was demonstrated cooperative effects in improvement of life quality, suppression of eosinophilic inflammation, and cough remission in patients with NAEB.

Show MeSH

Related in: MedlinePlus

Cough visual analog scale (CVAS). Changes of CVAS during 4 weeks treatment in montelukast (MONT) budesonide (BUD) group (Panel A) and BUD group (Panel B); Effects of 2-weeks (Panel C) and 4-weeks (Panel D) add-on montelukast treatment on decrease of CVAS. Data are expressed as median (10−90% range). *P < 0.05; **P < 0.01; ***P < 0.001, compared using Kruskal-Wallis test followed by Dunn's multiple comparison test. †P < 0.05, compared using Mann–Whitney test.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4837817&req=5

Figure 2: Cough visual analog scale (CVAS). Changes of CVAS during 4 weeks treatment in montelukast (MONT) budesonide (BUD) group (Panel A) and BUD group (Panel B); Effects of 2-weeks (Panel C) and 4-weeks (Panel D) add-on montelukast treatment on decrease of CVAS. Data are expressed as median (10−90% range). *P < 0.05; **P < 0.01; ***P < 0.001, compared using Kruskal-Wallis test followed by Dunn's multiple comparison test. †P < 0.05, compared using Mann–Whitney test.

Mentions: As demonstrated in Figure 2, compared with those baseline values, CVAS scores at 2-week in both treatment groups were decreased substantially (for MONT/BUD group, 47.88 ± 19.49 vs. 21.82 ± 13.10, P < 0.001; for BUD group, 44.38 ± 21.99 vs. 27.19 ± 16.11, P < 0.05). Additional reduction was proved in analyzing CVAS scores at 4-week (for MONT/BUD group, 8.49 ± 11.76; for BUD group, 13.13 ± 12.03, both P < 0.01, compared with CVAS of 2-week). In addition, after 2-week treatment, the decrease of CVAS was significantly different between MONT/BUD group and BUD group (26.06 ± 13.91 vs. 17.19 ± 17.64; P = 0.0210), which demonstrated add-on treatment of MONT was significantly more effective than BUD monotherapy for cough symptom alleviation. Similar results were seen at 4-week (39.39 ± 13.45 vs. 31.25 ± 19.30; P = 0.0415).


Efficacy of add-on montelukast in nonasthmatic eosinophilic bronchitis: the additive effect on airway inflammation, cough and life quality.

Bao W, Liu P, Qiu Z, Yu L, Hang J, Gao X, Zhou X - Chin. Med. J. (2015)

Cough visual analog scale (CVAS). Changes of CVAS during 4 weeks treatment in montelukast (MONT) budesonide (BUD) group (Panel A) and BUD group (Panel B); Effects of 2-weeks (Panel C) and 4-weeks (Panel D) add-on montelukast treatment on decrease of CVAS. Data are expressed as median (10−90% range). *P < 0.05; **P < 0.01; ***P < 0.001, compared using Kruskal-Wallis test followed by Dunn's multiple comparison test. †P < 0.05, compared using Mann–Whitney test.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4837817&req=5

Figure 2: Cough visual analog scale (CVAS). Changes of CVAS during 4 weeks treatment in montelukast (MONT) budesonide (BUD) group (Panel A) and BUD group (Panel B); Effects of 2-weeks (Panel C) and 4-weeks (Panel D) add-on montelukast treatment on decrease of CVAS. Data are expressed as median (10−90% range). *P < 0.05; **P < 0.01; ***P < 0.001, compared using Kruskal-Wallis test followed by Dunn's multiple comparison test. †P < 0.05, compared using Mann–Whitney test.
Mentions: As demonstrated in Figure 2, compared with those baseline values, CVAS scores at 2-week in both treatment groups were decreased substantially (for MONT/BUD group, 47.88 ± 19.49 vs. 21.82 ± 13.10, P < 0.001; for BUD group, 44.38 ± 21.99 vs. 27.19 ± 16.11, P < 0.05). Additional reduction was proved in analyzing CVAS scores at 4-week (for MONT/BUD group, 8.49 ± 11.76; for BUD group, 13.13 ± 12.03, both P < 0.01, compared with CVAS of 2-week). In addition, after 2-week treatment, the decrease of CVAS was significantly different between MONT/BUD group and BUD group (26.06 ± 13.91 vs. 17.19 ± 17.64; P = 0.0210), which demonstrated add-on treatment of MONT was significantly more effective than BUD monotherapy for cough symptom alleviation. Similar results were seen at 4-week (39.39 ± 13.45 vs. 31.25 ± 19.30; P = 0.0415).

Bottom Line: After 2-week treatment, add-on treatment of MONT was significantly more effective than BUD monotherapy for CVAS decrease and LCQ scores improvement (both P < 0.05).Similar results were seen at 4-week assessment (both P < 0.05). 4-week add-on therapy of MONT also resulted in a higher percentage of patients with normal sputum Eos (<2.5%) and greater decrease of ECP (both P < 0.05).MONT combined with BUD was demonstrated cooperative effects in improvement of life quality, suppression of eosinophilic inflammation, and cough remission in patients with NAEB.

View Article: PubMed Central - PubMed

Affiliation: Department of Respiratory Medicine, Shanghai First People's Hospital, Shanghai Jiao Tong University, Shanghai 200080, China.

ABSTRACT

Background: The efficacy of montelukast (MONT), a cysteinyl leukotriene receptor antagonist, in nonasthmatic eosinophilic bronchitis (NAEB), especially its influence on cough associated life quality is still indefinite. We evaluated the efficacy of MONT combined with budesonide (BUD) as compared to BUD monotherapy in improving life quality, suppressing airway eosinophilia and cough remission in NAEB.

Methods: A prospective, open-labeled, multicenter, randomized controlled trial was conducted. Patients with NAEB (aged 18-75 years) were randomized to inhaled BUD (200 μg, bid) or BUD plus oral MONT (10 μg, qn) for 4 weeks. Leicester cough questionnaire (LCQ) life quality scores, cough visual analog scale (CVAS) scores, eosinophil differential ratio (Eos), and eosinophil cationic protein (ECP) in induced sputum were monitored and compared.

Results: The control and MONT groups contained 33 and 32 patients, respectively, with similar baseline characteristics. Significant with-in group improvement in CVAS, LCQ scores, Eos, and ECP was observed in both groups during treatment. After 2-week treatment, add-on treatment of MONT was significantly more effective than BUD monotherapy for CVAS decrease and LCQ scores improvement (both P < 0.05). Similar results were seen at 4-week assessment (both P < 0.05). 4-week add-on therapy of MONT also resulted in a higher percentage of patients with normal sputum Eos (<2.5%) and greater decrease of ECP (both P < 0.05).

Conclusions: MONT combined with BUD was demonstrated cooperative effects in improvement of life quality, suppression of eosinophilic inflammation, and cough remission in patients with NAEB.

Show MeSH
Related in: MedlinePlus